#3-93E. Navigating Severe Behçet’s Syndrome: The 2025 EULAR Recommendations (ARD, 2026)

Have you ever struggled with the timing of initiating biologic agents for severe organ manifestations in Behçet's syndrome? In this episode, we explore the "EULAR recommendations for the management of Behçet’s syndrome: 2025 update," which provides the latest consensus on treatment algorithms categorized by organ involvement. Driven by recent systematic literature reviews, this update introduces five overarching principles and twelve tailored recommendations, emphasizing individualized care based on prognostic risk factors and multidisciplinary collaboration. The most crucial clinical shift in this paper is the strong recommendation for the early, upfront use of monoclonal tumor necrosis factor-alpha (TNFα) inhibitors in patients facing organ- or life-threatening complications, such as severe uveitis, vascular, or parenchymal neurological involvement. However, when critically appraising these guidelines, it is important to note that the evidence supporting some of the newer therapeutic agents still relies heavily on small trials or observational noncomparative studies with a high risk of bias. For the practicing physician, this updated framework is highly relevant, as it directly guides rapid, optimal, and individualized treatment decisions in daily clinical practice, ensuring aggressive intervention when irreversible organ damage is at stake.

Citation: Hatemi G, et al. EULAR recommendations for the management of Behçet’s syndrome: 2025 update. Annals of the Rheumatic Diseases. 2026. DOI: 10.1016/j.ard.2026.02.009

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.